ARWRbenzinga

B. Riley Securities Reiterates Buy on Arrowhead Pharma, Lowers Price Target to $38

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on February 14, 2025 by benzinga